\nThe outstanding debt securities listed in (i) the first table below labeled \u201cPool 1\u201d are referred to collectively as the \u201cPool 1 Notes\u201d and (ii) the second table below labeled \u201cPool 2\u201d are referred to collectively as the \u201cPool 2 Notes.\u201d The Pool 1 Notes and the Pool 2 Notes are referred to collectively as the \u201cNotes\u201d and each series of Notes is referred to as a \u201cseries.\u201d We refer to each offer to purchase a series of Notes for cash as an \u201cOffer,\u201d the offers to purchase the Pool 1 Notes collectively as the \u201cPool 1 Offers,\u201d the offers to purchase the Pool 2 Notes collectively as the \u201cPool 2 Offers,\u201d and all the offers to purchase Notes are referred to collectively as the \u201cOffers.\u201d<\/p>\n
\nBristol Myers Squibb\u2019s obligation to accept Notes tendered in the Offers is subject to the terms and conditions described in the Offer to Purchase dated November 3, 2025 (as amended or supplemented from time to time, the \u201cOffer to Purchase\u201d) which sets forth a detailed description of the Offers, including: (a) the Acceptance Priority Procedures (as defined in the Offer to Purchase) and (b) a limit of up to the maximum aggregate purchase price of Pool 1 Notes and Pool 2 Notes that may be purchased in the Offers.<\/p>\n
\nBristol Myers Squibb was advised by Global Bondholder Services Corporation, as the tender agent and information agent, that as of the Early Tender Deadline, the aggregate principal amounts of the Notes specified in the tables below were validly tendered and not validly withdrawn:<\/p>\n
Pool 1<\/b><\/p>\n
Offers to purchase for cash up to the Amended Pool 1 Maximum of the securities listed in the priority order below.<\/b><\/p>\n Acceptance<\/b><\/p>\n Priority Level<\/b><\/p>\n<\/td>\n Title of Security<\/b><\/p>\n<\/td>\n CUSIP\/ ISIN Number(s)<\/b><\/p>\n<\/td>\n Principal Amount<\/b><\/p>\n Outstanding<\/b><\/p>\n<\/td>\n Principal Amount Tendered<\/b><\/p>\n as of the Early Tender<\/b><\/p>\n Deadline<\/b><\/p>\n<\/td>\n<\/tr>\n \n1<\/p>\n<\/td>\n \n4.950% Notes due 2026<\/p>\n<\/td>\n \n110122ED6\/ US110122ED68<\/p>\n<\/td>\n \n$1,000,000,000<\/p>\n<\/td>\n \n$360,004,000<\/p>\n<\/td>\n<\/tr>\n \n2<\/p>\n<\/td>\n \n3.200% Notes due 2026<\/p>\n<\/td>\n \n110122CN6\/ US110122CN68\/ 110122CA4\/ US110122CA48\/ U11009BA1\/ USU11009BA16<\/p>\n<\/td>\n \n$1,749,998,000<\/p>\n<\/td>\n \n$529,929,000<\/p>\n<\/td>\n<\/tr>\n \n3<\/p>\n<\/td>\n \n4.900% Notes due 2027<\/p>\n<\/td>\n \n110122EE4\/ US110122EE42<\/p>\n<\/td>\n \n$1,000,000,000<\/p>\n<\/td>\n \n$519,484,000<\/p>\n<\/td>\n<\/tr>\n \n4<\/p>\n<\/td>\n \n3.900% Notes due 2028<\/p>\n<\/td>\n \n110122DE5\/ US110122DE50\/ 110122BQ0\/ US110122BQ09\/ U11009AQ7\/ USU11009AQ76<\/p>\n<\/td>\n \n$1,456,162,000<\/p>\n<\/td>\n \n$560,147,000<\/p>\n<\/td>\n<\/tr>\n \n5<\/p>\n<\/td>\n \n4.900% Notes due 2029<\/p>\n<\/td>\n \n110122EF1\/ US110122EF17<\/p>\n<\/td>\n \n$1,750,000,000<\/p>\n<\/td>\n \n$1,023,313,000<\/p>\n<\/td>\n<\/tr>\n \n6<\/p>\n<\/td>\n \n3.400% Notes due 2029<\/p>\n<\/td>\n \n110122CP1\/ US110122CP17\/ 110122CB2\/ US110122CB21\/ U11009BB9\/ USU11009BB98<\/p>\n<\/td>\n \n$2,399,977,000<\/p>\n<\/td>\n \n$972,783,000<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Pool 2<\/b><\/p>\n Offers to purchase for cash up to the Amended Pool 2 Maximum of the securities listed in the priority order below.<\/b><\/p>\n Acceptance<\/b><\/p>\n Priority Level<\/b><\/p>\n<\/td>\n Title of Security<\/b><\/p>\n<\/td>\n CUSIP\/ ISIN Number(s)<\/b><\/p>\n<\/td>\n Principal Amount<\/b><\/p>\n Outstanding<\/b><\/p>\n<\/td>\n Principal Amount Tendered<\/b><\/p>\n as of the Early Tender<\/b><\/p>\n Deadline<\/b><\/p>\n<\/td>\n<\/tr>\n \n1<\/p>\n<\/td>\n \n6.875% Debenture due 2097<\/p>\n<\/td>\n \n110122AC2\/ US110122AC22<\/p>\n<\/td>\n \n$62,417,000<\/p>\n<\/td>\n \n$6,178,000<\/p>\n<\/td>\n<\/tr>\n \n2<\/p>\n<\/td>\n \n6.400% Notes due 2063<\/p>\n<\/td>\n \n110122EC8\/ US110122EC85<\/p>\n<\/td>\n \n$1,250,000,000<\/p>\n<\/td>\n \n$879,216,000<\/p>\n<\/td>\n<\/tr>\n \n3<\/p>\n<\/td>\n \n6.250% Notes due 2053<\/p>\n<\/td>\n \n110122EB0\/ US110122EB03<\/p>\n<\/td>\n \n$1,250,000,000<\/p>\n<\/td>\n \n$811,465,000<\/p>\n<\/td>\n<\/tr>\n \n4<\/p>\n<\/td>\n \n5.650% Notes due 2064<\/p>\n<\/td>\n \n110122EL8\/ US110122EL84<\/p>\n<\/td>\n \n$1,750,000,000<\/p>\n<\/td>\n \n$1,309,768,000<\/p>\n<\/td>\n<\/tr>\n \n5<\/p>\n<\/td>\n \n5.900% Notes due 2033<\/p>\n<\/td>\n \n110122DZ8\/ US110122DZ89<\/p>\n<\/td>\n \n$1,000,000,000<\/p>\n<\/td>\n \n$493,578,000<\/p>\n<\/td>\n<\/tr>\n \n6<\/p>\n<\/td>\n \n5.750% Notes due 2031<\/p>\n<\/td>\n \n110122DY1\/ US110122DY15<\/p>\n<\/td>\n \n$1,000,000,000<\/p>\n<\/td>\n \n$412,855,000<\/p>\n<\/td>\n<\/tr>\n \n7<\/p>\n<\/td>\n \n5.550% Notes due 2054<\/p>\n<\/td>\n \n110122EK0\/ US110122EK02<\/p>\n<\/td>\n \n$2,750,000,000<\/p>\n<\/td>\n \n$1,917,650,000<\/p>\n<\/td>\n<\/tr>\n \n8<\/p>\n<\/td>\n \n5.200% Notes due 2034<\/p>\n<\/td>\n \n110122EH7\/ US110122EH72<\/p>\n<\/td>\n \n$2,500,000,000<\/p>\n<\/td>\n \n$1,468,075,000<\/p>\n<\/td>\n<\/tr>\n \n9<\/p>\n<\/td>\n \n5.100% Notes due 2031<\/p>\n<\/td>\n \n110122EG9\/ US110122EG99<\/p>\n<\/td>\n \n$1,250,000,000<\/p>\n<\/td>\n \n$666,525,000<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nSince any additional Pool 1 Notes that would be validly tendered after the Early Tender Deadline would exceed the Amended Pool 1 Maximum, Bristol Myers Squibb does not anticipate accepting any additional tenders of Pool 1 Notes in the Offers. Furthermore, because all of the Pool 1 Notes, and all of the Pool 2 Notes with an acceptance priority level at 1 through 4, that were validly tendered and not validly withdrawn prior to the Early Tender Deadline will be accepted for purchase by Bristol Myers Squibb, no proration procedures will be required for the Pool 1 and the Pool 2 Notes with an acceptance priority level at 1 through 4. Since the aggregate principal amount of 2033 Notes exceeds $250,000,000, Bristol Myers expects to accept the 2033 Notes on a prorated basis in accordance with the terms and conditions of the Offer to Purchase. No Pool 2 Notes with an acceptance priority level at 6 through 9, as set forth in the second table above, will be accepted for purchase.<\/p>\n \nThe withdrawal rights for the Offers expired at 5:00 p.m. (New York City time) on November 17, 2025. All conditions of the Offers were deemed satisfied or waived by Bristol Myers Squibb by the Early Tender Deadline. Bristol Myers Squibb has elected to exercise its Early Settlement Right (as defined in the Offer to Purchase). The Early Settlement Date (as defined in the Offer to Purchase) will occur on November 20, 2025. The Offers will each expire at 5:00 p.m. (New York City time) on December 3, 2025, unless extended or earlier terminated by Bristol Myers Squibb. However, since the aggregate principal amount of Pool 1 Notes and Pool 2 Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline met or exceeded the Amended Pool 1 Maximum and Amended Pool 2 Maximum, respectively, Bristol Myers Squibb expects that there will be no Final Settlement Date (as defined in the Offer to Purchase) and no tenders of Notes after the Early Tender Deadline will be accepted for purchase by Bristol Myers Squibb.<\/p>\n \nPromptly after 10:00 a.m. (New York City time) on November 18, 2025 (the \u201cPrice Determination Date\u201d), Bristol Myers Squibb intends to issue a press release specifying, among other things, (i) the aggregate principal amount of Notes accepted in each Offer, (ii) the offer yield, which is the applicable yield to the applicable par call date or maturity date, based on the price of the applicable Reference U.S. Treasury Security for that series as of the Price Determination Date plus the applicable fixed spread (as specified in the Offer to Purchase) (the \u201cOffer Yield\u201d) and (iii) the proration factor (if any) applied to validly tendered Notes in each Offer. All Holders of Notes (each, a \u201cHolder\u201d and collectively, \u201cHolders\u201d) whose Notes are accepted in an Offer will receive a cash payment equal to accrued and unpaid interest on such Notes to, but not including, the relevant Settlement Date (as defined in the Offer to Purchase) in addition to their Total Consideration or Tender Consideration, as applicable. For the avoidance of doubt, interest will cease to accrue on the relevant Settlement Date with respect to all Notes accepted for purchase on such Settlement Date. Under no circumstances will any interest be payable to Holders because of any delay on the part of Global Bondholder Services Corporation, as the tender agent and information agent, The Depository Trust Company or any other party in the transmission of funds to Holders. See the Offer to Purchase for additional information.<\/p>\n \nAll Notes accepted in the Offers will be cancelled and retired and will no longer remain outstanding obligations of Bristol Myers Squibb.<\/p>\n \nBristol Myers Squibb has retained Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC as lead dealer managers, BofA Securities, Inc., Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as dealer managers and Academy Securities, Inc. as a co-dealer manager for the Offers. Questions regarding terms and conditions of the Offers should be directed to Citigroup Global Markets Inc. at (800) 558-3745 (toll-free) or (212) 723-6106 (collect) or Deutsche Bank Securities Inc. at (866) 627-0391 (toll-free) or (212) 250-2955 (collect) or Goldman Sachs & Co. LLC at (800) 828-3182 (toll-free) or (212) 357-1452 (collect) or Morgan Stanley & Co. LLC at (800) 624-1808 (toll-free) or (212) 761-1057 (collect). Global Bondholder Services Corporation is acting as the tender agent and the information agent for the Offers (the \u201cTender and Information Agent\u201d).<\/p>\n Offer and Distribution Restrictions<\/span><\/b><\/p>\n \nThis announcement is for informational purposes only. This announcement is not an offer to sell or purchase, a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to any of Notes described herein. The Offers are being made solely pursuant to the Offer to Purchase. The Offers are not being made to Holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Offers to be made by a licensed broker or dealer, the Offers will be deemed to be made on behalf of Bristol Myers Squibb by the dealer managers or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction.<\/p>\n Cautionary Statement Regarding Forward-Looking Statements<\/span><\/b><\/p>\n \nThis press release contains certain forward-looking statements regarding, among other things, the timing, terms, conditions and other aspects of the Offers. You can identify these forward-looking statements by the fact that they use words such as \u201cshould,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201ctarget,\u201d \u201cmay,\u201d \u201cproject,\u201d \u201cguidance,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill\u201d and other words and terms of similar meaning and expression in connection with any discussion of, among other things, the Offers, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. No forward-looking statement can be guaranteed.<\/p>\n \nForward-looking statements are based on current expectations and projections about Bristol Myers Squibb\u2019s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them, that are difficult to predict, may be beyond its control and could cause its future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to: general market conditions which might affect the Offers; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; and access to capital markets.<\/p>\n \nForward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb\u2019s business and market, particularly those identified in the cautionary statement and risk factors discussion in its Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. The forward-looking statements included in this press release are made only as of the date of this press release and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.<\/p>\n About Bristol Myers Squibb: Transforming Patients\u2019 Lives Through Science<\/span><\/b><\/p>\n \nAt Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what\u2019s possible for the future of medicine and the patients we serve.<\/p>\n \ncorporatefinancial-news<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251117109482\/en\/<\/a><\/span><\/p>\n For more information:<\/span><\/b><\/p>\n M<\/b>edia Relations: Investor Relations: KEYWORDS:<\/b> New Jersey United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology Finance Health Professional Services Pharmaceutical<\/p>\n\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/p>\n
\n<\/b>
media@bms.com<\/a><\/p>\n
\n<\/b>
investor.relations@bms.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20251117109482\/en\/2041631\/3\/bms_logo_300_rgb_pos.jpg\"){kind=logo}
<\/td>\n<\/tr>\n